Vivian A. Fonseca, MD, has received research grants (to Tulane University) from GlaxoSmithKline, Novartis, Novo Nordisk, Takeda, AstraZeneca, Pfizer, sanofi-aventis, Eli Lilly & Co., Daiichi Sankyo, NIH, and ADA . He has received honoraria for consulting and lectures from GlaxoSmithKline, Novartis, Takeda, Novo Nordisk, sanofi-aventis, Eli Lilly & Co., and Daiichi Sankyo.
Allison Goldfine, MD, has served as a site investigator with Daiichi Sankyo and Eli Lilly & Co. She has received research support in the form of supplies from Caraco Pharmaceuticals; Lifescan, a Division of Johnson & Johnson; Medtronics; and Mercodia, and grant support (to Joslin Diabetes Center ) from the ADA , JDRF, NIH, and Dana Foundation. She is a member of the advisory board of Tethys Bioscience. She has received honoraria for consulting from CV Therapeutics, Daiichi Sankyo, Merck, and Novo Nordisk.
Michael Nauck, MD, PhD, is a member of the advisory boards of Amylin Pharmaceuticals, ConjuChem, Eli Lilly & Co., GlaxoSmithKline, Hoffman La Roche, Novartis, Novo Nordisk, Probiodrug, Restoragen (BioNebraska), and sanofi-aventis, He has received honoraria or consulting fees from AstraZeneca, Bayer Vital Pharma, Berlin Chemie/Menarini, Biovitrum, ConjuChem, Eli Lilly & Co., Hoffman La Roche, Merck, MSD, Novartis, Novo Nordisk, Pfizer, Probiodrug, Restoragen (BioNebraska), sanofi-aventis, and Takeda. He has received grants and research support from Amylin Pharmaceuticals, Bayer Vital Pharma, Leverkusen, Eli Lilly & Co., Menarini/Berlin-Chemie, Novartis, Novo Nordisk, sanofi-aventis, Probiodrug, and Restoragen (BioNebraska).
Jorge Plutzky, MD, has received grant/research support from sanofi-aventis and consulting fees or honoraria from Amylin Pharmaceuticals, Inc.; Dainippon Sumitomo Pharma America, Inc.; GlaxoSmithKline; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.; and Tethys Bioscience.
Bernard Zinman, MD, receives grant/research support from GlaxoSmithKline, Merck & Co., Inc., and Novo Nordisk A/S. He has received honorarium and/or consulting fees from Eli Lilly & Company, GlaxoSmithKline, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, A/S, Boehringer-Ingelheim, and sanofi-aventis.